AwesomeCapital

Omega Healthcare Investors Q3 Earnings Preview

Omega Healthcare Investors (NYSE:OHI) is scheduled to announce Q3 earnings results on Tuesday, November 5th, after market close.

The consensus FFO Estimate is $0.76 (-1.3% Y/Y) and the consensus Revenue Estimate is $194.26M (-12.4% Y/Y).

Over the last 2 years, ohi has beaten FFO estimates 50% of the time and has beaten revenue estimates 50% of the time.

Over the last 3 months, FFO estimates have seen 0 upward revisions and 5 downward. Revenue estimates have seen 3 upward revisions and 1 downward.

https://seekingalpha.com/news/3513738-omega-healthcare-investors-q3-earnings-preview

Amarin Q3 2019 Earnings Preview

Amarin (NASDAQ:AMRN) is scheduled to announce Q3 earnings results on Tuesday, November 5th, before market open.

The consensus EPS Estimate is -$0.04 (+33.3% Y/Y) and the consensus Revenue Estimate is $110.04M (+98.9% Y/Y).

Over the last 2 years, amrn has beaten EPS estimates 63% of the time and has beaten revenue estimates 75% of the time.

Over the last 3 months, EPS estimates have seen 4 upward revisions and 0 downward. Revenue estimates have seen 3 upward revisions and 2 downward.

https://seekingalpha.com/news/3513717-amarin-q3-2019-earnings-preview

Mirati Therapeutics EPS misses by $0.13, beats on revenue

Mirati Therapeutics (NASDAQ:MRTX): Q3 GAAP EPS of -$1.38 misses by $0.13.

Revenue of $0.99M beats by $0.78M.

Shares +1.05%.

Press Release

https://seekingalpha.com/news/3514065-mirati-therapeutics-eps-misses-0_13-beats-revenue

MyoKardia EPS misses by $1.06

MyoKardia (NASDAQ:MYOK): Q3 GAAP EPS of -$3.07 misses by $1.06.

Cash and equivalents of $235.16M

Shares +0.24%.

Press Release

https://seekingalpha.com/news/3514075-myokardia-eps-misses-1_06

Endo Q3 top line down 2%; ytd cash flow down 40%

Endo International (NASDAQ:ENDP) Q3 results:

Revenues: $729.4M (-2.2%); Branded Pharma: $217M (-1.4%); Specialty Products: $132M (+17.9%); Sterile Injectables: $264M (+11.4%).

Net loss: ($41.4M) (+71.7%); non-GAAP net income: $138.1M (-16.2%); loss/share: ($0.18) (+72.3%); non-GAAP EPS: $0.60 (+15.5%); non-GAAP EBITDA: $321.1M (-2.2%).

Cash flow ops (9 mo.): $119.2M (-39.5%).

2019 guidance: Revenues: $2.86B – 2.89B from $2.76B – 2.96B; non-GAAP EPS: $2.10 – 2.25 from $2.00 – 2.25; non-GAAP EBITDA: $1.26B – 1.30B from $1.24B – 1.34B.

https://seekingalpha.com/news/3514081-endo-q3-top-line-2-percent-ytd-cash-flow-40-percent-shares-3-percent-hours